Lactiplantibacillus plantarum P101 Mitigates Alcoholic Steatosis Through AMPK Activation: Mechanistic Insights and Research Implications

Study Background and Research Question

Alcoholic liver disease (ALD) is a major global health concern, accounting for approximately 3 million deaths annually, primarily due to long-term excessive alcohol intake. The earliest pathophysiological manifestation of ALD is alcoholic fatty liver disease (AFLD), characterized by hepatic triglyceride (TG) accumulation and metabolic dysregulation. While AFLD is reversible, progression to fibrosis and cirrhosis occurs in a significant subset of patients. Given the reversibility of early-stage AFLD, interventions targeting hepatic lipid accumulation are of particular clinical interest (reference study).

5′-Adenosine monophosphate-activated protein kinase (AMPK) is a master regulator of lipid metabolism, modulating the balance between anabolic and catabolic pathways in hepatocytes. Downregulation of AMPK activity, often observed following alcohol exposure, disrupts this balance, promoting lipid accumulation. Nutritional interventions, especially probiotics, are increasingly studied for their capacity to restore metabolic homeostasis. The present research addresses whether the probiotic Lactiplantibacillus plantarum P101 (LP.P101) can attenuate alcohol-induced hepatic lipid accumulation via AMPK pathway modulation. A secondary focus explores the role of gut microbiota and metabolite changes in mediating these effects.

Key Innovation from the Reference Study

The core innovation lies in demonstrating, with mechanistic clarity, that LP.P101 alleviates alcohol-induced hepatic lipid accumulation through activation of the AMPK signaling pathway. This is substantiated by integrating gut microbiota profiling and serum metabolomics, revealing that shifts in microbial composition and metabolic signatures are closely linked to AMPK activity and hepatic lipid content.

Notably, the study employs the pharmacological AMPK inhibitor Dorsomorphin to delineate the pathway’s role, thereby providing direct evidence that the probiotic’s protective effect is AMPK-dependent. This approach moves beyond associative findings, offering a causal mechanistic link between probiotic intervention, AMPK activation, and hepatic lipid regulation (reference study).

Methods and Experimental Design Insights

The experimental framework involved a short-term (10-day) plus binge ethanol feeding protocol in mice to induce hepatic steatosis, simulating early-stage AFLD. Mice received daily gavage of LP.P101 at 10⁸ CFU/mL. To interrogate the mechanistic role of AMPK, a subset of animals was co-treated with Dorsomorphin, an established small-molecule AMPK inhibitor.

• Liver histopathology and Oil Red O staining assessed lipid droplet accumulation.
• Biochemical assays quantified serum alanine aminotransferase (ALT) and hepatic triglycerides (TG).
• Western blot and RT-qPCR measured AMPK phosphorylation and downstream gene expression.
• 16S rRNA gene sequencing profiled gut microbiota alterations.
• Untargeted metabolomics characterized serum metabolic shifts.

By including Dorsomorphin as a selective AMPK pathway inhibitor, the study could directly compare the metabolic and histological outcomes with and without functional AMPK signaling, thereby clarifying the pathway’s necessity for the probiotic effect.

Protocol Parameters

• Ethanol feeding: 10-day Lieber-DeCarli liquid diet with ethanol, followed by a binge dose (single high ethanol gavage) to model AFLD.
• Probiotic administration: LP.P101 at 10⁸ CFU/mL via daily oral gavage throughout the ethanol feeding period.
• AMPK inhibition: Dorsomorphin was administered (dose as per referenced protocols) to a subset of animals to block AMPK activity during intervention.
• Sample collection: Livers harvested for histology and molecular assays; serum collected for biochemical and metabolomic analysis.

Suggested adaptations for related workflows may include titrating Dorsomorphin concentrations based on preliminary in vivo tolerability, and time-course sampling to capture dynamic changes in AMPK activation and lipid metabolism.

Core Findings and Why They Matter

LP.P101 administration significantly reduced hepatic lipid droplet accumulation in ethanol-fed mice, as evidenced by histological analysis. This effect was accompanied by decreased serum ALT and liver TG levels, indicating both structural and functional hepatoprotection. Mechanistically, these improvements were linked to increased AMPK phosphorylation and normalization of related gene expression, including inhibition of SREBP1c (lipogenesis) and activation of PPARα (fatty acid oxidation).

Critically, co-administration of Dorsomorphin abolished these benefits: hepatic lipid content, ALT, and AMPK-regulated gene expression reverted to levels observed in the alcohol-only group. This confirms that AMPK activation is essential for the observed probiotic effect (reference study).

Beyond the liver, LP.P101 altered the gut microbiota, decreasing the relative abundance of Firmicutes and increasing Bacteroidetes—changes associated with improved metabolic health. Taxonomic analysis revealed that Parabacteroides merdae inversely correlated with lipid accumulation, while certain Negativibacillus taxa negatively tracked with AMPK activation. Metabolomics identified serum stercobilinogen as a potential biomarker, showing a positive correlation with AMPK activation and negative association with hepatic lipid content. These data suggest a gut-liver axis, where probiotic-induced metabolic and microbial changes converge on AMPK signaling to mitigate steatosis.

Comparison with Existing Internal Articles

The reference study’s mechanistic dissection parallels and extends concepts elucidated in recent internal articles. For example, "L. plantarum P101 Attenuates Alcoholic Steatosis via AMPK Activation" provides an early overview of the probiotic’s impact on hepatic lipid metabolism through AMPK, emphasizing the translational potential of dietary interventions. Meanwhile, "Dorsomorphin 2HCl: Shaping Translational Research in AMPK and BMP Pathways" details the pharmacological rationale and workflow guidance for using Dorsomorphin as a research tool to dissect AMPK and BMP-dependent processes across metabolic and bone biology models.

This reference paper advances the field by integrating both pharmacological inhibition and multi-omics approaches, establishing a causal pathway and identifying new microbial and metabolic biomarkers. Such a combination of experimental rigor and systems-level analysis is less common in prior literature and provides a more robust foundation for future research on probiotic-AMPK interactions.

Limitations and Transferability

Despite its strengths, the study is limited by its short-term murine model, which may not fully recapitulate the chronic pathophysiology of human ALD. The effects of LP.P101 on other stages of liver disease, and in genetically diverse backgrounds, remain to be established. Additionally, while Dorsomorphin is a widely used AMPK inhibitor, it also has activity against BMP type I receptors and may influence other signaling pathways, potentially confounding interpretation in some settings (product information).

The transferability of observed gut microbiota and metabolite signatures to human populations requires further validation, as mouse and human microbiomes exhibit both overlap and distinct characteristics. Finally, the study’s focus on LP.P101 leaves open whether other probiotic strains might exert similar or complementary effects via AMPK or other metabolic pathways.

Research Support Resources

Researchers aiming to model AMPK-dependent metabolic regulation, or to replicate the reference study’s workflow, can utilize Dorsomorphin 2HCl (SKU B1372) as a selective inhibitor of AMPK and BMP signaling. This reagent supports precise interrogation of pathway dependencies in both in vitro and in vivo systems, enabling studies of hepatic lipid metabolism, osteogenic differentiation inhibition, and iron homeostasis regulation. For additional technical guidance on application and troubleshooting, consult recent reviews such as "Dorsomorphin 2HCl: Applied AMPK Inhibition in Metabolic Workflows". Proper use of AMPK inhibitors, with attention to solubility and dose optimization, is essential for accurate interpretation of pathway-specific effects in metabolic research.